Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
NCT00344331 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900
Last updated 2026-05-01
Summary
This study will evaluate clinical and laboratory tests that might be useful in determining if an investigational drug can slow the progression of Niemann-Pick Disease, Type C (NPC), a genetic disorder that results in progressive loss of nervous system function. The study will: 1) look for a clinical or biochemical marker that can be used as a measure of response to treatment, and 2) define the rate of progression of biochemical marker abnormalities in a group of NPC patients who will later be invited to enroll in a treatment trial.
Patients of any age with NPC may be eligible for this study. Participants undergo the following procedures every 6 months during 4- to 5-day admissions at the NIH Clinical Center.
* Medical evaluation, including medical history, physical exam, neurological exam, neuropsychometric evaluation, and blood and urine tests.
* Lumbar puncture (spinal tap): A sample of cerebrospinal fluid (CSF), the fluid that bathes the brain and spinal cord, is obtained for study. After administration of a local anesthetic, a small needle is inserted in the space between the bones in the lower back where the CSF circulates below the spinal cord. A small amount of fluid is collected through the needle.
* Eye exam and eye movement study: The pupils of the eye are dilated to examine the structures of the eyes. For the eye movement study a special contact lens is placed on the eye and the patient looks at a series of target light spots moving on a screen.
* Hearing tests.
* Electroretinography (in patients who can cooperate with the test) to measure the function of the retina. Before the test, the patient's pupils are dilated and an electrode (small silver disk) is taped to the forehead. The patient sits in a dark room for 30 minutes and then a special contact lens is placed on one eye after it has been numbed with drops. The contact lens senses small electrical signals generated by the retina when lights flash. During the ERG recording, the eye is stimulated with flashes of light projected inside a hollow sphere. After the test, a full eye exam is done and photographs of the retina are taken.
* Magnetic resonance imaging (MRI): This test uses a magnetic field and radio waves to produce images of the brain and obtain information about brain chemicals. The patient lies on a table that can slide in and out of the scanner (a narrow cylinder), wearing earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. Patients who cannot remain still in the scanner may be sedated for the test.
* Psychometric testing: Patients complete questionnaires.
* Photographs of the patient may be taken for use in teaching sessions or scientific presentations or publications, with the patient's consent. Patients may be recognizable, but are not identified by name.
* Pregnancy test in all female patients over 10 years of age at the beginning of each admission to the Clinical Center.
Conditions
- Niemann-Pick Disease, Type C
Sponsors & Collaborators
-
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
lead NIH
Principal Investigators
-
Forbes D Porter, M.D. · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Eligibility
- Min Age
- 1 Day
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-08-14
Countries
- United States
Study Locations
More Related Trials
-
Miglustat in Niemann-Pick Type C Disease
NCT00517153 ·Status: COMPLETED ·Phase: PHASE2
-
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
NCT03759639 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725 ·Status: RECRUITING ·Phase: PHASE3
-
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients
NCT04098211 ·Status: ACTIVE_NOT_RECRUITING
-
Safety and Efficacy of Miglustat in Chinese NPC Patients
NCT03910621 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Phenotypic Variability in Fabry Disease
NCT03145779 ·Status: WITHDRAWN
-
Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C
NCT03893071 ·Status: UNKNOWN ·Phase: PHASE1
-
Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
NCT03879655 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Facioscapulohumeral Dystrophy in Children
NCT02625662 ·Status: COMPLETED
-
Natural History Study of Patients With VCP-related Disease
NCT04823143 ·Status: COMPLETED
-
Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease
NCT03687476 ·Status: WITHDRAWN ·Phase: PHASE2
-
Application of Miglustat in Patients With Niemann-Pick Type C
NCT01760564 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)
NCT02939547 ·Status: COMPLETED ·Phase: PHASE1
-
The Natural History of Infantile Globoid Cell Leukodystrophy
NCT00983879 ·Status: COMPLETED
-
Investigating Lysosomal Storage Diseases in Minority Groups
NCT02120235 ·Status: UNKNOWN
-
Natural History Studies of Mucopolysaccharidosis III
NCT02037880 ·Status: COMPLETED
-
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
NCT05418049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
NCT00076102 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Enzyme Replacement in Gaucher's Disease
NCT00001289 ·Status: COMPLETED
-
Induced Pluripotent Stem Cells for Niemann Pick Disease
NCT03883750 ·Status: COMPLETED
-
Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
NCT05758922 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency
NCT00157118 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Longitudinal Studies of the Glycoproteinoses
NCT01891422 ·Status: COMPLETED
-
PCD New Gene Discovery
NCT03801395 ·Status: COMPLETED
-
Studies in Patients With Tuberous Sclerosis Complex
NCT03276195 ·Status: COMPLETED